Previous studies have demonstrated the efficiency of HDAC inhibitors in reducing cardiac hypertrophy under pathological conditions [33,34] and in attenuating structural remodelling after myocardial infarction [35]. The gene discussed is HDAC9; the disease is cardiac hypertrophy.